PART I . Overview We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Our pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted age...
Q2 FY2026 — expected 2026-08-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001171843-26-001337 | EDGAR | 81K words |
| 2025-02-27 | 2024-12-31 | 0001171843-25-001106 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0001171843-24-001516 | EDGAR | — |
| 2023-03-15 | 2022-12-31 | 0001171843-23-001691 | EDGAR | — |
| 2022-03-18 | 2021-12-31 | 0000950170-22-004156 | EDGAR | — |
| 2021-03-05 | 2020-12-31 | 0001564590-21-011110 | EDGAR | — |
| 2020-06-08 | 2020-03-31 | 0001213900-20-014390 | EDGAR | — |
| 2019-07-01 | 2019-03-31 | 0001213900-19-011850 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001171843-26-005295 | EDGAR | — |
| 2025-11-05 | 2025-09-30 | 0001171843-25-007005 | EDGAR | 14K words |
| 2025-08-11 | 2025-06-30 | 0001171843-25-005261 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001171843-25-002953 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001171843-24-006248 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0001171843-24-004670 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001171843-24-002785 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001171843-23-006912 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001171843-23-004947 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001171843-23-002868 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001171843-22-007269 | EDGAR | — |
| 2022-08-01 | 2022-06-30 | 0001171843-22-005187 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001171843-26-005292 | EDGAR | — |
| 2026-03-05 | 0001171843-26-001336 | EDGAR | 2K words |
| 2026-01-06 | 0001171843-26-000083 | EDGAR | — |
| 2025-11-05 | 0001171843-25-007004 | EDGAR | — |
| 2025-08-13 | 0001193125-25-179958 | EDGAR | — |
| 2025-08-11 | 0001171843-25-005260 | EDGAR | — |
| 2025-06-12 | 0001171843-25-003868 | EDGAR | — |
| 2025-05-08 | 0001171843-25-002952 | EDGAR | — |
| 2025-04-01 | 0001171843-25-001900 | EDGAR | — |
| 2025-02-27 | 0001171843-25-001105 | EDGAR | — |
104 total filings indexed. 74 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001738021 |
| Ticker | CMPX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.compasstherapeutics.com |
| Listed | 2020-11-13 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CMPX (~200 tokens, structured JSON with cryptographic provenance)